Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2469-2473

  Carpentier, Antoine F ^a,b   Xie, Jun ^a   Mokhtari, Karima ^b   Delattre, Jean Yves ^a  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PURIFICATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; GLIOMA; IMMUNOSTIMULATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIGENS, CD8; BRAIN NEOPLASMS; CANCER VACCINES; CPG ISLANDS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MICE; MICE, NUDE; MICROGLIA; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES; RATS; RATS, INBRED LEW; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034087729     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cowdery, J. S., Chace, J. H., Yi, A. K., and Krieg, A. M. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol., 156: 4570-4575, 1996.
2. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol., 157: 1840-1845, 1996.
3. Halpern, M. D., Kurlander, R. J., and Pisetsky, D. S. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell. Immunol., 167: 72-78, 1996.
4. Chace, J. H., Hooker, N. A., Mildenstein, K. L., Krieg, A. M., and Cowdery, J. S. Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol., 84: 185-193, 1997.
5. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (Lond.), 374: 546-549, 1995.
6. Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med., 3: 849-854, 1997.
7. Lipford, G. B., Sparwasser, T., Bauer, M., Zimmermann, S., Koch, E. S., Heeg, K., and Wagner, H. Immunostimulatory DNA. sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol., 27: 3420-3426, 1997.
8. Brooks, W. H., Netsky, M. G., Normansell, D. E., and Horwitz, D. A. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med., 136: 1631-1647, 1972.
9. Miescher, S., Whiteside, T. L., Carrel, S., and Von Fliedner, V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136: 1899-1907, 1986.
10. Elliott, L. H., Brooks, W. H., and Roszman, T. L. Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J. Clin. Invest., 86: 80-86, 1990.
11. 2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol. (Berl.), 69: 278-282, 1986.
12. Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., and Fontana, A. Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J. Immunol., 143: 3222-3229, 1989.
13. Huettner, C., Paulus, W., and Roggendorf, W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol., 146: 3173-3122, 1995.
14. Saijo, Y., Perlaky, L., Wang, H., and Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res., 6: 243-249, 1994.
15. Kruse, C. A., Molleston, M. C., Parks, E. P., Schiltz, P. M., Kleinschmidt-DeMasters, B. K., and Hickey, W. F. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J. Neuro-oncol., 22: 191-200, 1994.
16. Carpentier, A. F., Chen, L., Maltonti, F., and Delattre, J. Y. Oligodeoxynucleotides containing CpG motifs can cure neuroblastoma in mice. Cancer Res., 59: 5429-5432, 1999.
17. Tokunaga, T., Yamamoto, H., Shimada, S., Abe, H., Fukuda, T., Fujisawa, Y., Furutani, Y., Yano, O., Kataoka, T., and Sudo, T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst., 72: 955-962, 1984.
18. Nakaichi, M., Takeuchi, A., Shitara, N., and Takakura, K. The antitumor activity of the DNA fraction from Mycobacterium bovis BCG (MY-1) for glioblastoma. J. Vet. Med. Sci., 57: 583-585, 1995.
19. Crooke, R. M. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des., 6: 609-646, 1991.
20. Kishima, H., Shimizu, K., Miyao, Y., Mabuchi, E., Tamura, K., Tamura, M., Sasaki, M., and Hakakawa, T. Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system. Br. J. Cancer, 78: 446-453, 1998.
21. Jean, W. C., Spellman, S. R., Wallenfriedman, M. A., Hall, W. A., and Low, W. C. Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery, 42: 850-856, 1998.
22. Krieg, A. M., Love-Homan, L., Yi, A. K., and Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol., 161: 2428-2434, 1998.
23. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., and Sherman, M. L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 3: 409-417, 1997.
24. Davis, H. L., Weeranta, R., Waldschmidt, T. J., Tygrett, L., Schorr, J., and Krieg, A. M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol., 160: 870-876, 1998.
25. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., and Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1997.